公开(公告)号：US11491152B2

公开(公告)日：2022-11-08

申请号：US17700947

申请日：2022-03-22

Applicant: BOW RIVER LLC

Inventor： Sundar Srinivasan ,  Christina Chow Wallen

IPC: A61K31/496 ,  A61P35/00 ,  A61P35/02 ,  A61P25/18 ,  A61P25/16 ,  A61P35/04 ,  A61K9/00 ,  A61K9/08 ,  A61K9/10 ,  A61K9/20 ,  A61K9/48 ,  A61K31/00 ,  A61K31/397 ,  A61K31/407 ,  A61K31/4468 ,  A61K31/454 ,  A61K31/4745 ,  A61K31/497 ,  A61K31/498 ,  A61K31/4995 ,  A61K31/506 ,  A61K31/519 ,  A61K31/5383 ,  A61K31/5395

Abstract: The present disclosure provides for methods of treating a patient with a CYP3A4 substrate drug, wherein the patient is treated with posaconazole. In some embodiments, the patient stops posaconazole treatment, waits for at least 2 days, and then is treated with the CYP3A4 substrate drug as soon as it is safe to do so. In some embodiments, treatment with the CYP3A4 substrate drug is delayed for about 2-42 days after stopping posaconazole. In some embodiments, the patient is treated with a reduced dose of the CYP3A4 substrate drug for about 2-42 days.

公开(公告)号：US11458206B2

公开(公告)日：2022-10-04

申请号：US16793094

申请日：2020-02-18

Applicant: TVA (ABC), LLC

Inventor： Rossitza G. Alargova ,  Mark T. Bilodeau ,  Craig A. Dunbar ,  Sudhakar Kadiyala ,  Rajesh R. Shinde ,  Patrick Lim Soo ,  Beata Sweryda-Krawiec ,  Brian H. White ,  Patrick Rosaire Bazinet ,  Richard Wooster

IPC: A61K51/00 ,  A61K47/64 ,  A61K47/65 ,  A61K31/337 ,  A61K47/55 ,  A61K31/5383

Abstract: Nanoparticles and microparticles, and pharmaceutical formulations thereof, containing conjugates of an active agent such as a therapeutic, prophylactic, or diagnostic agent attached to a targeting moiety, such as a somatostatin receptor binding moiety, via a linker have been designed. Such nanoparticles and microparticles can provide improved temporospatial delivery of the active agent and/or improved biodistribution. Methods of making the conjugates, the particles, and the formulations thereof are provided. Methods of administering the formulations to a subject in need thereof are provided, for example, to treat or prevent cancer or infectious diseases.

公开(公告)号：US20220304988A1

公开(公告)日：2022-09-29

申请号：US17639003

申请日：2021-06-04

Applicant: ZHEJIANG UNIVERSITY OF TECHNOLOGY

Inventor： Hong WANG ,  Jianwei CHEN ,  Yaojia LU ,  Huawei ZHANG ,  Bin WEI

IPC: A61K31/437 ,  A61K38/12 ,  A61K31/407 ,  A61K31/5383 ,  A61P31/04

Abstract: The present invention discloses an application of norharmane in improving activity of an antibiotic in resisting bacteria, when norharmane of the present invention is combined with polymyxin B, imipenem-cilastatin sodium or levofloxacin, it can enhance antibacterial activity of the antibiotic against drug-resistant Pseudomonas aeruginosa, produce a synergistic antibacterial effect, and significantly improves the killing ability of antibiotics against drug-resistant Pseudomonas aeruginosa to reduce the amount of antibiotics needed for achieving the same therapeutic effect, thereby providing a research direction for the development of new drugs and new use of old drugs.

公开(公告)号：US20220249459A1

公开(公告)日：2022-08-11

申请号：US17727455

申请日：2022-04-22

Applicant: BOW RIVER LLC

Inventor： Sundar SRINIVASAN ,  Christina CHOW WALLEN

IPC: A61K31/4468 ,  A61K9/10 ,  A61K31/5395 ,  A61K31/506 ,  A61K31/407 ,  A61K31/454 ,  A61K31/519 ,  A61K9/00 ,  A61K9/08 ,  A61P25/18 ,  A61P25/16 ,  A61K9/48 ,  A61K31/497 ,  A61P35/02 ,  A61K9/20 ,  A61K31/397 ,  A61K31/4995 ,  A61K31/4745 ,  A61P35/04 ,  A61K31/00 ,  A61K31/5383 ,  A61K31/498

Abstract: The present disclosure provides for methods of treating a patient with a CYP3A4 substrate drug, wherein the patient is treated with posaconazole. In some embodiments, the patient stops posaconazole treatment, waits for at least 2 days, and then is treated with the CYP3A4 substrate drug as soon as it is safe to do so. In some embodiments, treatment with the CYP3A4 substrate drug is delayed for about 2-42 days after stopping posaconazole. In some embodiments, the patient is treated with a reduced dose of the CYP3A4 substrate drug for about 2-42 days.

公开(公告)号：US11345672B2

公开(公告)日：2022-05-31

申请号：US16688469

申请日：2019-11-19

Applicant: Valo Health, Inc.

Inventor： Jennifer Lee ,  Nicholas Barczak ,  Jaime A. Escobedo ,  Chiara Conti ,  Bingsong Han ,  David R. Lancia, Jr. ,  Cuixian Liu ,  Matthew W. Martin ,  Pui Yee Ng ,  Aleksandra Rudnitskaya ,  Jennifer R. Thomason ,  Xiaozhang Zheng

IPC: C07D263/58 ,  A61P35/00 ,  A61K31/403 ,  A61K31/404 ,  A61K31/4178 ,  A61K31/4184 ,  A61K31/4188 ,  A61K31/4192 ,  A61K31/422 ,  A61K31/423 ,  A61K31/4245 ,  A61K31/427 ,  A61K31/428 ,  A61K31/435 ,  A61K31/437 ,  A61K31/438 ,  A61K31/4439 ,  A61K31/4709 ,  A61K31/4985 ,  A61K31/506 ,  A61K31/52 ,  A61K31/5377 ,  A61K31/5383 ,  A61K45/06 ,  C07C53/06 ,  C07D209/40 ,  C07D209/54 ,  C07D221/20 ,  C07D235/30 ,  C07D277/82 ,  C07D401/04 ,  C07D401/06 ,  C07D401/14 ,  C07D403/04 ,  C07D403/06 ,  C07D405/04 ,  C07D413/06 ,  C07D413/12 ,  C07D413/14 ,  C07D417/06 ,  C07D473/00 ,  C07D487/04 ,  C07D491/056 ,  C07D491/107 ,  C07D498/04

Abstract: The present invention provides methods and uses of inhibitors of histone deacetylase 11 (HDAC11) in the treatment of diseases and/or disorders, such as, for example, cell proliferative diseases.

公开(公告)号：US11306106B2

公开(公告)日：2022-04-19

申请号：US16937877

申请日：2020-07-24

Applicant: Shionogi & Co., Ltd.

Inventor： Makoto Kawai

IPC: C07D498/14 ,  A61P31/16 ,  A61P31/12 ,  A61P43/00 ,  A61K31/5383

Abstract: The present invention provides a pharmaceutical composition containing the following compound having antiviral action: wherein each of the symbols is defined in the specification.

公开(公告)号：US20220098181A1

公开(公告)日：2022-03-31

申请号：US17517428

申请日：2021-11-02

Applicant: Rigel Pharmaceuticals, Inc.

Inventor： Hui Li ,  Sambaiah Thota ,  David Carroll ,  Ankush Argade ,  Kin Tso ,  Arvinder Sran ,  Jeffrey Clough ,  Holger Keim ,  Somasekhar Bhamidipati ,  Vanessa Taylor ,  Robin Cooper ,  Rajinder Singh ,  Brian Wong

IPC: C07D413/12 ,  C07D403/04 ,  C07D239/42 ,  C07D401/12 ,  C07D403/12 ,  C07D413/14 ,  C07D239/48 ,  A61K31/343 ,  A61K31/436 ,  A61K31/505 ,  A61K31/506 ,  A61K31/5377 ,  A61K31/538 ,  A61K31/5383 ,  A61K31/541 ,  A61K31/695 ,  A61K38/13 ,  A61K39/395 ,  C07D498/04 ,  C07F7/10 ,  A61K45/06 ,  C07D401/14 ,  C07D417/12 ,  C07F7/08

Abstract: The invention encompasses compounds having formula I-V and the compositions and methods using these compounds in the treatment of conditions in which modulation of the JAK pathway or inhibition of JAK kinases, particularly JAK3, may be therapeutically useful.

公开(公告)号：US20220096465A1

公开(公告)日：2022-03-31

申请号：US17443769

申请日：2021-07-27

Applicant: Inflammatory Response Research, Inc.

Inventor： Bruce Chandler May

IPC: A61K31/495 ,  A61K38/14 ,  A61K45/06 ,  A61K31/407 ,  A61K31/424 ,  A61K31/43 ,  A61K31/431 ,  A61K31/47 ,  A61K31/496 ,  A61K31/505 ,  A61K31/5383 ,  A61K31/546 ,  A61K31/635 ,  A61K31/65 ,  A61K31/7052 ,  A61K31/7056

Abstract: The embodiments described herein include methods and formulations for treating lung and brain injury. The methods and formulations include, but are not limited to, methods and formulations for delivering effective concentrations of levocetirizine and montelukast to a patient in need. The methods and formulations can comprise conventional and/or modified-release elements, providing for drug delivery to the patient.

公开(公告)号：US11279711B2

公开(公告)日：2022-03-22

申请号：US16795884

申请日：2020-02-20

Applicant: Newave Pharmaceutical Inc.

Inventor： Yi Chen ,  Yan Lou

IPC: C07D498/14 ,  C07D513/14 ,  A61P35/00 ,  A61P37/00 ,  A61P35/02 ,  A61P35/04 ,  A61K31/5383 ,  A61K31/542 ,  A61K45/06

Abstract: The disclosure includes compounds of Formula (A): wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, and R12, j, k, m, n, Y, W, W1, W2, W3, V, L, Z1, Q1, Q2, Q3, and Q4, are defined herein. Also disclosed is a method for treating a neoplastic disease, an autoimmune disease, or a neorodegenerative disease with these compounds.

公开(公告)号：US20220080047A1

公开(公告)日：2022-03-17

申请号：US17240273

申请日：2021-04-26

Applicant: Horizon Orphan LLC

Inventor： Michael N. DUDLEY ,  Ruslan Y. TSIVKOVSKI ,  David C. GRIFFITH ,  Olga RODNY

IPC: A61K45/06 ,  A61K31/7036 ,  A61K33/06 ,  A61P11/00 ,  A61P11/06 ,  A61K31/538 ,  A61P29/00 ,  A61K31/5383 ,  A61K31/536 ,  C07D498/14 ,  A61K47/02

Abstract: The present invention relates to methods and compositions for the treatment of pulmonary inflammation. In particular, methods and compositions using aerosol levofloxacin or ofloxacin to reduce pulmonary inflammation are provided.